-
New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?
06 February 2012
Ahmad Awada, Ivana Bozovic-Spasojevic, Louis Chow
Summary: Overexpression of the human epidermal growth factor receptor 2 (HER2) predicts a poor prognosis in metastatic breast cancer. While the introduction of HER2-targeted therapies, such as the mon...
-
Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit
30 January 2012
Stéphane Oudard, Reza-Thierry Elaidi
Abstract: Multiple targeted agents are now available for the treatment of patients with metastatic renal cell carcinoma (mRCC). Although targeted agents offer improvements over previous treatments and...
-
Treatment of elderly patients with glioblastoma: From clinical evidence to molecular highlights
30 January 2012
Cyrus Chargari, Loïc Feuvret, Olivier Bauduceau, Damien Ricard, Xavier Cuenca, Jean-Yves Delattre, Jean-Jacques Mazeron
Abstract: Elderly patients with glioblastoma are characterized by a high rate of associated morbidities, and a poor prognosis. Therefore, they have been excluded from most prospective clinical trials....
-
Uveal melanoma
24 January 2012
Francesco Spagnolo, Graziano Caltabiano, Paola Queirolo
Abstract: Uveal melanoma, which arises from melanocytes residing in the stroma, is the most common primary intraocular tumor in adults. Up to 50% of patients with primary uveal melanoma will ultimatel...
-
A preclinical and clinical review of aflibercept for the management of cancer
24 January 2012
Andrew Gaya, Vivien Tse
Abstract: Aflibercept, also known as vascular endothelial growth factor (VEGF)–Trap, is a recombinant, decoy receptor fusion protein, rationally designed to block angiogenesis by targeting not only al...
View More Articles in Press...
